-
Story
Prioritizing the needs of patients -
Story
Expanding a new digital healthcare solution across chronic heart disease management -
Press ReleaseNovartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
-
Press ReleaseNovartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
-
Press ReleaseNovartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy